Sign up

AcclaimIP-ad

Match Document Document Title
8940712 Micro-RNA family that modulates fibrosis and uses thereof  
The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29...
8940683 Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors  
The present invention is drawn to methods and compositions for treating inflammatory disorders of the lower airways, comprising administering an effective amount of an agent, which modulates the...
8940713 Micro-RNA family that modulates fibrosis and uses thereof  
The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29...
8940709 Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules  
The present invention, at least in part, relates to the discovery of efficacious delivery of an RNAi agent (in preferred aspects of the invention, an siRNA) to a transplantable tissue. Organ...
8940299 Method of treating cancer  
A method for inducing apoptosis of a neoplastic cell expressing C3aR or C5aR includes administering at least one complement antagonist to the cell so that the at least one complement antagonist...
8940711 Micro-RNA family that modulates fibrosis and uses thereof  
The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29...
8940708 Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF  
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Hepatocyte Growth Factor (HGF), in particular, by targeting natural antisense...
8936910 Method for selective oligonucleotide modification  
Method for producing a modified oligonucleotide, wherein at least one polymer, preferably polyalkylene oxide, and/or a compound is covalently bound to the 5′-end or the 3′-end of the oli...
8936942 Polyethyleneglycol-modified lipid compounds and uses thereof  
The present invention provides compositions comprising polytheylyene-dialkyloxypropyl conjugates (PEG-DAA), liposomes, SNALP, and SPLP comprising such compositions, and methods of using such...
8933045 Modulation of human cytomegalovirus replication by micro-RNA 132 (miR132), micro-RNA 145 (mi145) and micro-RNA 212 (miR212)  
The present invention related to miR145, miR132, miR212, and the genes or gene products regulated by these miRNAs. miR145 is downregulated in cells infected with HCMV. This downregulation modulates...
8933042 Methods for controlling pests using RNAi  
The present invention relates to methods for controlling pest infestation using double stranded RNA molecules. The invention provides methods for producing transgenic cells expressing the double...
8933049 Repressor on IFN-λ promoter and siRNA against ZEB1 and BLIMP-1 to increase IFN-λ gene activity  
The present invention is directed to the identification of a novel repressor located between ˜1.2 kb to ˜1.6 kb from the translation start site of the IFN-λ1 promoter. The present invention pr...
8933046 Influenza targets  
The present invention relates to a pharmaceutical composition comprising an inhibitor of influenza virus replication. Yet another aspect is a screening method for identification of new targets for...
8933047 Poly(acrylate) polymers for in vivo nucleic acid delivery  
The present invention is directed membrane active poly(acrylate) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides cells in vivo. RNAi polynucleotides are...
8933050 Methods for the treatment and the diagnosis of cancer  
The present invention relates to methods for the diagnostic and the staging of cancer such as liver cancer. The present invention also relates to methods for the treatment of cancer including liver...
8933043 Methods for regulation of p53 translation and function  
The present invention relates to novel methods for modulating the activity of p53 tumor suppressor protein by affecting p53 translational regulation. More specifically, the invention relates to...
8927510 Compositions and methods for inhibition of retroviruses  
Described herein are methods and compositions for the inhibition of retroviral integration and replication. The methods and compositions inhibit the activity of one or more components of the SET...
8927515 Methods and compositions for the specific inhibition of androgen receptor by double-stranded RNA  
This invention relates to compounds, compositions, and methods useful for reducing AR target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
8927519 Methods for producing interfering RNA molecules in mammalian cells and therapeutic uses for such molecules  
Methods for producing interfering RNA molecules in mammalian cells are provided. Therapeutic uses for the expressed molecules, including inhibiting expression of HIV, are also provided.
8927516 Combination of DNA repair inhibition with bendamustine or gemcitabine in the treatment of cancer  
The invention provides methods for enhancing the cytotoxicity of DNA damage in cancer cells that express thymine DNA glycosylase, and treating tumors accordingly. The methods comprise inhibiting...
8927514 Recombinant adeno-associated vectors for targeted treatment  
Novel adeno-associated virus (AAV) vectors in nucleotide and amino acid forms and uses thereof are provided. The isolates show specific tropism for certain target tissues, such as blood stem cells,...
8921329 Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO  
Oligonucleotide compounds modulate expression and/or function of Erythropoietin (EPO) polynucleotides and encoded products thereof. Methods for treating diseases associated with Erythropoietin...
8920832 Composition for nucleic acid transfection  
The invention provides a nucleic-acid-transfecting composition which exhibits low cytotoxicity, which facilitates an effective nucleic acid transfection into a cell, and which improves expression...
8916531 Modulation of CD40 expression  
Disclosed herein are antisense compounds and methods for decreasing CD40. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to CD40...
8916596 Preventing or treating viral infection using an inhibitor of the LSD1 protein, a MAO inhibitor or an inhibitor of LSD1 and a MAO inhibitor  
An embodiment of the invention provides preventing or treating a viral infection of a host, comprising administering to the host an effective amount of an inhibitor of the protein LSD1 and/or a...
8916534 Methods of inducing insulin production  
The present invention provides a method of inducing insulin production in a cell by up-regulating a target gene involved in insulin production in said cell using an saRNA (short activating...
8916529 Oligonucleotide-containing pharmacological compositions and their use  
The present invention relates to methods and compositions containing oligonucleotides suitable for administration to humans and other mammals.
8916694 SNPs of apolipoprotein B and modulation of their expression  
Compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein B....
8911777 Pharmaceutical composition of tacrolimus  
An oral tacrolimus composition comprises minicapsules having a core containing tacrolimus in a solubilized liquid form. The minicapsules have a release profile to release the pre-solubilized...
8912158 Method for treating myocardial infarct  
The invention relates to a method for influencing the miR-92 expression in a cell, comprising the following steps: (a) providing a cell; and (b1) reducing the miR-92 expression in the cell in order...
8912155 Method for analyzing secretome, biomarker for lung cancer metastasis, and siRNA compound for inhibiting lung cancer metastasis  
A method for analyzing secretome, a biomarker for lung cancer metastasis, and a siRNA compound for inhibiting lung cancer metastasis are disclosed. The method for analyzing secretome of the present...
8912160 Methods for treating hypercholesterolemia  
Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating,...
8912159 Analyzing semaphorin7a (Sema7A) levels for assessing cancer metastatic potential and methods of treatment  
Methods, assays, and kits for determining a cancer's (e.g., breast cancer) metastatic potential and tumor aggressiveness in a subject (e.g., a human patient) and for measuring a subject's response...
8906871 MicromiRs  
The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
8906877 Method for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis  
Disclosed are methods for identification of agents that modulate cell attachment, cell migration and cell viability. Cancer and primary cells adhered to a matrix are treated with agent(s) that...
8906870 MicroRNA (miRNA) for the diagnosis and treatment of heart diseases  
The invention relates to microRNAs (miRNAs) for the diagnosis, prophylaxis and/or treatment of heart diseases. It relates in particular to SEQ ID No: 1 to SEQ ID No: 29 for the diagnosis,...
8907077 siRNA targeting TIE-2  
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene...
8900627 Compositions for the in vivo delivery of RNAi agents  
This application describes emulsion formulations containing neutral phospholipids for delivering RNAi, anti-miRNA, or aptamer agents in vivo. The application also relates to methods of making the...
8901098 Antisense modulation of GCCR expression  
Provided herein are methods, compounds, and compositions for reducing expression of GCCR mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent,...
8901097 Methods for delivery of siRNA to the spinal cord and therapies arising therefrom  
The present application relates at least in part to methods for the administration of small interfering RNAs (siRNAs) to the spinal cord of a human or animal patient and also to a method of...
8901101 Membrane lytic poly(amido amine) polymers for the delivery of oligonucleotides  
The present invention provides membrane lytic poly(amido amine) polymers, polyconjugates, compositions and methods for the delivery of oligonucleotides for therapeutic purposes.
8895521 Methods and compositions for the treatment of uveitis  
Pharmaceutical compositions are disclosed that are of use for the treatment of uveitis. These compositions include a suppressive oligonucleotide. These compositions including an immunosuppressive...
8895529 Antisense modulation of fibroblast growth factor receptor 4 expression  
Antisense compounds, compositions and methods are provided for modulating the expression of fibroblast growth factor receptor 4 (FGFR4). The compositions comprise antisense compounds, particularly...
8895524 Viral microRNA  
The present invention relates, in general, to micro RN As and, in particular, to viral microRNAs expressed by Herpes Simplex Vims 1 (HSV-1) or Herpes Simplex Virus 2 (HSV-2), to agents that inhibit...
8895527 Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3  
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Transcription factor E3 (TFE3) and/or Insulin Receptor Substrate 2 (IRS2)...
8895526 Identification of RNAI targets and use of RNAI for rational therapy of chemotherapy-resistant leukemia and other cancers  
Provided is a mosaic mouse model for use in determining the potency of an shRNA in vivo for reducing survival of cancer cells of chemotherapy-resistant leukemia. The syngeneic mouse recipient is...
8889648 Nucleic acid having an anti-metabolic syndrome effect  
The problem of the present invention is to prove a medicament for decreasing body weigh, a medicament for decreasing visceral fat, a medicament for decreasing triglyceride in the liver, and a...
8889649 Composition containing antisense oligonucleotide to micro RNA  
Provided is a composition that contains an antisense oligonucleotide to a micro RNA and is capable of inhibiting the growth of cancer cells. The present invention, as one aspect, relates to a...
8889646 Nucleic acid modulators of glycoprotein VI  
The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of...
8889645 Nucleic acid modulators of glycoprotein VI  
The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of...